149-91-7
[1]CurrentPatentAssignee:MITSUBISHICHEMICALHOLDINGSCORPORATION-EP1854795,2007,A1Locationinpatent:Page/Pagecolumn12
[1]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-US9518048,2016,B2
[1]Patent:US9518048,2016,B2
[1]CurrentPatentAssignee:PUYERNANTONGBIOPHARMA-CN106349237,2017,ALocationinpatent:Paragraph0043;0044;0059
[2]CurrentPatentAssignee:KONGOCHEM-JP2021/161096,2021,ALocationinpatent:Paragraph0057
[1]Patent:CN106349237,2017,A
Title: Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20180601
Title: Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Journal: Vascular pharmacology 20170901
Title: A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Journal: European journal of pharmacology 20121205
Title: Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Journal: Diabetes, obesity & metabolism 20121101
Title: Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry 20121001
Title: Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202.
Title: Ideta T, et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015 Dec 8;16(12):29207-18.
